Lek Supervisory Board adopts 2003 Annual Report
At its regular meeting today, the Supervisory Board of Lek Pharmaceuticals d.d. discussed the Report on the Business Performance of the joint-stock company Lek in the year 2003, together with the Annual Report and the Auditor’s Report. The Supervisory Board adopted the Annual Report and approved the proposal for the employment of the distributable net profit to be submitted to the General Meeting of the joint-stock company for adoption.
The company will allocate SIT 6.545 m for dividends, which amounts to 24% of the net profit from the previous year.
The Supervisory Board also approved the business plan and targets for 2004. With regard to last year’s excellent results the board expressed its appreciation to the Lek Board of Management, managers and all employees.
The 2003 Annual Report of Lek Pharmaceuticals d.d. was audited by PricewaterhouseCoopers, d.o.o., Ljubljana, which gave a positive assessment of the financial statements on April 2, 2004.
The Supervisory Board extended the mandate of the Lek Board of Management.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
- * *
For further details contact Katarina Klemenc Dinjaški, Corporate Communications at Lek, ++ 386 1 580 22 43, firstname.lastname@example.org